AGR2 could serve as a biomarker for the prognosis of metastasis and chemotherapeutic response in breast cancer [53,54], lung cancer [15], gastric cancer [12], esophageal squamous cell carcinoma [55]. This evidence concerns the gene AGR2 and lung carcinoma.